Hansa Biopharma AB (OSTO:HNSA) EV-to-EBIT : -4.53 (As of May. 24, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hansa Biopharma AB's Enterprise Value is kr3,160.1 Mil. Hansa Biopharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-697.1 Mil. Therefore, Hansa Biopharma AB's EV-to-EBIT for today is -4.53.

The historical rank and industry rank for Hansa Biopharma AB's EV-to-EBIT or its related term are showing as below:

OSTO:HNSA' s EV-to-EBIT Range Over the Past 10 Years
Min: -67.42 Med: -18.61 Max: -1.53
Current: -4.55

During the past 13 years, the highest EV-to-EBIT of Hansa Biopharma AB was -1.53. The lowest was -67.42. And the median was -18.61.

OSTO:HNSA's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 10.43 vs OSTO:HNSA: -4.55

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Hansa Biopharma AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr1,938.4 Mil. Hansa Biopharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-697.1 Mil. Hansa Biopharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -35.96%.

Hansa Biopharma AB EV-to-EBIT Historical Data

The historical data trend for Hansa Biopharma AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB EV-to-EBIT Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-7.70

-22.15

-5.65

-3.31

-2.09

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-3.64	-3.04	-2.49	-2.09	-2.78

Competitive Comparison of Hansa Biopharma AB's EV-to-EBIT

For the Biotechnology subindustry, Hansa Biopharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansa Biopharma AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's EV-to-EBIT falls into.

Hansa Biopharma AB EV-to-EBIT Calculation

Hansa Biopharma AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	3160.109	/	-697.099
	=	-4.53

Hansa Biopharma AB's current Enterprise Value is kr3,160.1 Mil.
Hansa Biopharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-697.1 Mil.

Hansa Biopharma AB (OSTO:HNSA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hansa Biopharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-697.099	/	1938.40638
	=	-35.96 %

Hansa Biopharma AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr1,938.4 Mil.
Hansa Biopharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-697.1 Mil.

Hansa Biopharma AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines